ArticleNature neuroscience2026
Modeling maternal immune activation in 3D ex vivo human fetal brain cerebroids reveals IL-17A-driven disruption of cortical development.
Article in Nature neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Maternal immune activation (MIA) disrupts brain development and increases the risk of neurodevelopmental disorders, yet the mechanisms by which MIA impacts human cortical development remain poorly understood. Here we introduce a three-dimensional ex vivo culture system, termed 'cerebroids,' derived from the dorsolateral prefrontal cortex of human fetal brain tissue, which preserves the key developmental processes, cellular diversity and structural integrity of the developing human cortex. Using this model, we show that IL-17A, a cytokine implicated in MIA and neurodevelopmental disorders, induces premature cortical folding, increases cortical thickness and accelerates neurogenesis and neuronal maturation. We reveal that IL-17A substantially dysregulates extracellular-matrix-related pathways, including upregulation of proteoglycans. In neural stem cells, IL-17A directly activates NF-κB signaling, leading to sustained inflammatory responses that contribute to these developmental abnormalities, which are reversed by treatment with the NF-κB pathway inhibitor parthenolide. These findings delineate how IL-17A perturbs human corticogenesis while elucidating the mechanisms underlying brain disruption during MIA.
Indexed as
Identifiers
42581194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.